e l f Beauty Inc vs Zimmer Biomet Holdings Inc — how do they compare? e l f Beauty Inc trades at $94.65 (market cap $5.62B), while Zimmer Biomet Holdings Inc trades at $97 (market cap $18.65B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 3.3× e l f Beauty Inc's market cap, and Zimmer Biomet Holdings Inc pays a 0.98% dividend while e l f Beauty Inc pays none. Which is the better fit depends on your goals.
| ELF | ZBH | |
|---|---|---|
Market Cap | $5.62B | $18.65B |
Sector | Technology | Health |
52-Week High | $146.67 | $107.71 |
52-Week Low | $49.57 | $79.58 |
Enterprise Value | $6.20B | $25.72B |
Dividend Yield | — | 0.98% |
Signals from Pluang's Aura AI — not financial advice
ELF trades at $98.49, up 6.69% in 24 hours, near its 52-week high. The stock exhibits a bullish technical trend with strong support at $93 and resistance at $101. Recent Q2 2026 earnings beat expectations with EPS of $1.75 versus $0.71 expected, driven by 36% revenue growth and the Rhode acquisition. The company raised fiscal 2027 guidance, reflecting robust demand and international expansion.
Outlook remains positive due to consistent sales growth and strategic initiatives, but risks include high valuation (P/E 97.18) and reliance on acquisitions for growth. The stock offers growth potential but faces margin pressure from increased investments and competitive dynamics in the beauty sector.
No Aura AI signal available yet.
Trailing returns across standard periods
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →